The following stocks are the leading risers and fallers on AIM in London on Tuesday.
----------
AIM - WINNERS
----------
Abingdon Health PLC, up 12% at 12.00 pence, 12-month range 7.00p-94.72p. Enters into two ‘strategic’ collaborations. One with diagnostic technology firm Vatic Health Ltd and another with Abingdon’s fellow AIM listing DeepVerge PLC. DeepVerge shares were 3.0% higher. With Vatic, Abingdon will work towards a commercial pact for the development and manufacture of a range of lateral flow tests for infectious diseases, initially focused on influenza. Abingdon also teams with DeepVerge for lateral flow tests. The tie-up will supply DeepVerge’s Modern Water and Life Science arms. Modern Water monitors toxicity in water, soil and food, while Life Science produces home tests for stress levels, skin changes, and disorders such as diabetes. In addition, Abingdon posts results for the six months ended December 31. Revenue falls to £1.7 million from £7.7 million a year earlier. It posts no Department of Health & Social Care revenue during the period, compared to £4.4 million a year prior, amid a billing dispute.
----------
XLMedia PLC, up 7.9% at 30.65 pence, 12-month range 0.24p-31.00p. The marketing firm’s stock hits a one-year high after it posts a 21% revenue increase to $66.5 million in 2021 from $54.8 million in 2020. Pretax profit surges to $4.0 million from $1.1 million.
----------
AIM - LOSERS
----------
Driver Group PLC, down 23% at 29.90p, 12-month range 24.88p-71.49p. The Lancashire-based engineering services provider says it suffered a ‘difficult’ second quarter, which concludes on Thursday. A problematic pact in the Asia-Pacific region and a drop in revenue in the Middle East hurt results for the quarter. First half pretax profit could fall by more than half. Driver forecasts pretax profit of between £300,000 and £500,000 for the half year, down from £1.0 million a year prior. In addition, it says Chief Financial Officer David Kilgour tenders his resignation. ‘The recruitment process will commence immediately to identify a suitable replacement to ensure a smooth transition,’ Driver says
----------
SkinBioTherapeutics PLC, down 18% at 37.44p, 12-month range 25.07p-88.00p. The Macclesfield, England-based life science company, focused on skin health, warns its annual revenue will be ‘materially below market expectations’. Revenue in the half year ended December 31 amounts to £21,949, versus none a year earlier. Pretax loss widens to £1.2 million from £628,241. ‘While current sales are materially below budget they are growing and expected to be significantly increased by enhanced marketing spend,’ SkinBioTherapeutics says.
----------
Copyright 2022 Alliance News Limited. All Rights Reserved.
